Advertisement
Canada markets open in 9 hours 7 minutes

  • S&P/TSX

    21,885.38
    +11.66 (+0.05%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • CAD/USD

    0.7323
    -0.0000 (-0.00%)
     

  • CRUDE OIL

    83.86
    +0.29 (+0.35%)
     

  • Bitcoin CAD

    87,725.52
    +169.67 (+0.19%)
     

  • CMC Crypto 200

    1,389.06
    +6.48 (+0.47%)
     

  • GOLD FUTURES

    2,346.90
    +4.40 (+0.19%)
     

  • RUSSELL 2000

    1,981.12
    -14.31 (-0.72%)
     

  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     

  • NASDAQ futures

    17,767.00
    +199.50 (+1.14%)
     

  • VOLATILITY

    15.37
    -15.97 (-50.96%)
     

  • FTSE

    8,078.86
    +38.48 (+0.48%)
     

  • NIKKEI 225

    37,892.67
    +264.19 (+0.70%)
     

  • CAD/EUR

    0.6827
    +0.0006 (+0.09%)
     

Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Novartis AG (NVS)

ACCESSWIRE

NEW YORK, NY / ACCESSWIRE / August 30, 2019 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Novartis AG(“Novartis” or the Company”) (NASDAQ:NVS). Investors are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: www.bgandg.com/nvs.

The investigation concerns whether Novartis and certain of its officers and/or directors have violated federal securities laws.

On August 6, 2019, the U.S. Food and Drug Administration (“FDA”) announced that Novarits had submitted its biologics license application (“BLA”) for its gene therapy drug, Zolgensma, and that data in the application had been manipulated. The announcement continued to state that the Company “became aware of the issue of the data manipulation that created inaccuracies in their BLA before the FDA approved the product yet did not inform the FDA until after the product was approved.” Novartis is currently under FDA investigation and may be subject to further penalties.

Following this news, Novartis stock dropped $2.50 per share, or roughly 3%, to close at $88.22 on August 6, 2019.

ADVERTISEMENT

If you are aware of any facts relating to this investigation, or purchased Novartis shares,you can assist this investigation by visiting the firm’s site: www.bgandg.com/nvs. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC



View source version on accesswire.com:
https://www.accesswire.com/558023/Bronstein-Gewirtz-Grossman-LLC-Announces-Investigation-of-Novartis-AG-NVS